KRT18 as a Novel Biomarker of Urothelial Papilloma While Evaluating Low-Grade Papillary Urothelial Neoplasms: Bi-Center Analysis

Minsun Jung,Bohyun Kim,Jae Seok Lee,Jun Yong Kim,Dohyun Han,Kwangsoo Kim,Sunah Yang,Eun Na Kim,Hyeyooon Kim,Ilias P Nikas,Sohyeon Yang,Kyung Chul Moon,Hyebin Lee,Han Suk Ryu
DOI: https://doi.org/10.1159/000540926
2024-08-27
Pathobiology
Abstract:Introduction: Although urothelial papilloma (UP) is an indolent papillary neoplasm that can mimic the morphology of low-grade papillary urothelial carcinoma (PUC), there is no immunomarker to differentiate reliably these two entities. In addition, the molecular characteristics of UP are not fully understood. Methods: We conducted an in-depth proteomic analysis of papillary urothelial lesions (n=31), including UP and PUC along with normal urothelium. Protein markers distinguishing UP and PUC were selected with machine learning analysis, followed by internal and external validation using immunohistochemistry. Results: In the proteomic analysis, UP and PUC showed overlapping proteomic profiles. We identified EHD4 and KRT18 as candidate diagnostic biomarkers of UP. Through immunohistochemical validation in two independent cohorts (n=120), KRT18 was suggested as a novel UP diagnostic marker, able to differentiate UP from low-grade PUC. We also found that 3.5% of patients with UP developed urothelial carcinoma in subsequent resections, supporting the malignant potential of UP. KRT18 downregulation was significantly associated with UPs subsequently progressing to urothelial carcinoma, following their initial diagnosis. Conclusion: This is the first study that successfully revealed UP's comprehensive proteomic landscape, while it also identified KRT18 as a potential diagnostic biomarker of UP.
What problem does this paper attempt to address?